---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-029006"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:16:24.028600+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics Q4 2022 revenue $3.3M, net loss $30.3M; FY22 revenue $41.9M

## Summary
- Q4 2022 total revenue $3.3M (incl. $1.1M collaborative revenue from KORSUVA profit share); FY22 total revenue $41.9M.
- Q4 2022 net loss $30.3M ($0.56 per share); FY22 net loss $85.5M ($1.59 per share).
- Cash and equivalents $156.7M at Dec 31, 2022; expects to fund operations into first half of 2024.
- KORSUVA injection net sales $2.3M in Q4, $35.3M for FY22; wholesaler shipments 20,844 vials in Q4, 207,096 for FY22.
- Phase 2/3 program of oral difelikefalin for NP initiated; PMDA decision in Japan expected H2 2023.

## SEC filing metadata
- accession: 0001104659-23-029006
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/0001104659-23-029006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/tm238541d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-029006
- JSON: https://secwatch.observer/filing/0001104659-23-029006.json
- Plain text: https://secwatch.observer/filing/0001104659-23-029006.txt

## Key facts
- Earnings Releases
  Tvardi Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
  - Period: the fourth quarter and year ended December 31, 2022
  - Result: reported results
  source text: On March 6, 2023, Cara Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1346830/000110465923029006/0001104659-23-029006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.